NEW YORK (GenomeWeb) – Blueprint Medicines today announced a collaboration with Alexion to discover, develop, and commercialize novel drug candidates for an unnamed, kinase-related, rare genetic disease. An activated kinase target, which was also not named, is the cause of the disease.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.